KRAS and neoplasm: The seminal study testing the impact of removing functional mitochondria by suppression of the mitochondrial transcription factor A (TFAM) demonstrated a reduction of tumor burden, highlighting the requirement for mitochondrial metabolism and ROS in KRAS-driven tumor development (39).